MedTrace Logo

A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

NCT02991430 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-06-19

Study results available
· View outcomes & findings →

Summary

This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

Conditions

  • Intervention

Interventions

DEVICE

active neuromodulation for episodic migraine headache

Non-invasive brainstem neuromodulator. Active and placebo devices appear identical

DEVICE

placebo neuromodulation for episodic migraine headache

Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical

Sponsors & Collaborators

  • Scion NeuroStim

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2018-05-11
Completion
2018-05-11
FDA Device
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991430 on ClinicalTrials.gov